Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 41

1.

Mechanisms and Clinical Significance of Pharmacokinetic-Based Drug-Drug Interactions with Drugs Approved by the U.S. Food and Drug Administration in 2017.

Yu J, Petrie ID, Levy RH, Ragueneau-Majlessi I.

Drug Metab Dispos. 2019 Feb;47(2):135-144. doi: 10.1124/dmd.118.084905. Epub 2018 Nov 15.

PMID:
30442649
2.

Risk of Clinically Relevant Pharmacokinetic-Based Drug-Drug Interactions with Drugs Approved by the U.S. Food and Drug Administration Between 2013 and 2016.

Yu J, Zhou Z, Tay-Sontheimer J, Levy RH, Ragueneau-Majlessi I.

Drug Metab Dispos. 2018 Jun;46(6):835-845. doi: 10.1124/dmd.117.078691. Epub 2018 Mar 23.

PMID:
29572333
3.

Physiologically Based Pharmacokinetic Model of the CYP2D6 Probe Atomoxetine: Extrapolation to Special Populations and Drug-Drug Interactions.

Huang W, Nakano M, Sager J, Ragueneau-Majlessi I, Isoherranen N.

Drug Metab Dispos. 2017 Nov;45(11):1156-1165. doi: 10.1124/dmd.117.076455. Epub 2017 Aug 31.

4.

Intestinal Drug Interactions Mediated by OATPs: A Systematic Review of Preclinical and Clinical Findings.

Yu J, Zhou Z, Tay-Sontheimer J, Levy RH, Ragueneau-Majlessi I.

J Pharm Sci. 2017 Sep;106(9):2312-2325. doi: 10.1016/j.xphs.2017.04.004. Epub 2017 Apr 13. Review.

PMID:
28414144
5.

What Can Be Learned from Recent New Drug Applications? A Systematic Review of Drug Interaction Data for Drugs Approved by the US FDA in 2015.

Yu J, Zhou Z, Owens KH, Ritchie TK, Ragueneau-Majlessi I.

Drug Metab Dispos. 2017 Jan;45(1):86-108. Epub 2016 Nov 7. Review.

6.

Investigating ABCB1-Mediated Drug-Drug Interactions: Considerations for In vitro and In vivo Assay Design.

Sáfár Z, Vaskó B, Ritchie TK, Imre G, Mogyorósi K, Erdő F, Rajnai Z, Fekete Z, Szerémy P, Muka L, Zolnerciks JK, Herédi-Szabó K, Ragueneau-Majlessi I, Krajcsi P.

Curr Drug Metab. 2016;17(5):430-55. Review.

PMID:
26728264
7.

Key Findings from Preclinical and Clinical Drug Interaction Studies Presented in New Drug and Biological License Applications Approved by the Food and Drug Administration in 2014.

Yu J, Ritchie TK, Zhou Z, Ragueneau-Majlessi I.

Drug Metab Dispos. 2016 Jan;44(1):83-101. doi: 10.1124/dmd.115.066720. Epub 2015 Sep 30. Review.

8.

Organ Impairment-Drug-Drug Interaction Database: A Tool for Evaluating the Impact of Renal or Hepatic Impairment and Pharmacologic Inhibition on the Systemic Exposure of Drugs.

Yeung CK, Yoshida K, Kusama M, Zhang H, Ragueneau-Majlessi I, Argon S, Li L, Chang P, Le CD, Zhao P, Zhang L, Sugiyama Y, Huang SM.

CPT Pharmacometrics Syst Pharmacol. 2015 Aug;4(8):489-94. doi: 10.1002/psp4.55. Epub 2015 Jul 14.

9.

Physiologically Based Pharmacokinetic (PBPK) Modeling and Simulation Approaches: A Systematic Review of Published Models, Applications, and Model Verification.

Sager JE, Yu J, Ragueneau-Majlessi I, Isoherranen N.

Drug Metab Dispos. 2015 Nov;43(11):1823-37. doi: 10.1124/dmd.115.065920. Epub 2015 Aug 21. Review.

10.

Breast cancer resistance protein (ABCG2) in clinical pharmacokinetics and drug interactions: practical recommendations for clinical victim and perpetrator drug-drug interaction study design.

Lee CA, O'Connor MA, Ritchie TK, Galetin A, Cook JA, Ragueneau-Majlessi I, Ellens H, Feng B, Taub ME, Paine MF, Polli JW, Ware JA, Zamek-Gliszczynski MJ.

Drug Metab Dispos. 2015 Apr;43(4):490-509. doi: 10.1124/dmd.114.062174. Epub 2015 Jan 13. Review.

11.

Drug disposition and drug-drug interaction data in 2013 FDA new drug applications: a systematic review.

Yu J, Ritchie TK, Mulgaonkar A, Ragueneau-Majlessi I.

Drug Metab Dispos. 2014 Dec;42(12):1991-2001. doi: 10.1124/dmd.114.060392. Epub 2014 Sep 30. Review.

12.

Evaluation of various static in vitro-in vivo extrapolation models for risk assessment of the CYP3A inhibition potential of an investigational drug.

Vieira ML, Kirby B, Ragueneau-Majlessi I, Galetin A, Chien JY, Einolf HJ, Fahmi OA, Fischer V, Fretland A, Grime K, Hall SD, Higgs R, Plowchalk D, Riley R, Seibert E, Skordos K, Snoeys J, Venkatakrishnan K, Waterhouse T, Obach RS, Berglund EG, Zhang L, Zhao P, Reynolds KS, Huang SM.

Clin Pharmacol Ther. 2014 Feb;95(2):189-98. doi: 10.1038/clpt.2013.187. Epub 2013 Sep 18.

PMID:
24048277
13.

Application of receiver operating characteristic analysis to refine the prediction of potential digoxin drug interactions.

Ellens H, Deng S, Coleman J, Bentz J, Taub ME, Ragueneau-Majlessi I, Chung SP, Herédi-Szabó K, Neuhoff S, Palm J, Balimane P, Zhang L, Jamei M, Hanna I, O'Connor M, Bednarczyk D, Forsgard M, Chu X, Funk C, Guo A, Hillgren KM, Li L, Pak AY, Perloff ES, Rajaraman G, Salphati L, Taur JS, Weitz D, Wortelboer HM, Xia CQ, Xiao G, Yamagata T, Lee CA.

Drug Metab Dispos. 2013 Jul;41(7):1367-74. doi: 10.1124/dmd.112.050542. Epub 2013 Apr 25.

14.

Predicting substrates of the human breast cancer resistance protein using a support vector machine method.

Hazai E, Hazai I, Ragueneau-Majlessi I, Chung SP, Bikadi Z, Mao Q.

BMC Bioinformatics. 2013 Apr 15;14:130. doi: 10.1186/1471-2105-14-130.

15.

Importance of multi-p450 inhibition in drug-drug interactions: evaluation of incidence, inhibition magnitude, and prediction from in vitro data.

Isoherranen N, Lutz JD, Chung SP, Hachad H, Levy RH, Ragueneau-Majlessi I.

Chem Res Toxicol. 2012 Nov 19;25(11):2285-300. doi: 10.1021/tx300192g. Epub 2012 Sep 27. Review.

16.

e-PKGene: a knowledge-based research tool for analysing the impact of genetics on drug exposure.

Hachad H, Overby CL, Argon S, Yeung CK, Ragueneau-Majlessi I, Levy RH.

Hum Genomics. 2011 Jul;5(5):506-15. Review.

17.
18.

Interaction between clopidogrel and proton pump inhibitors: hypothesis to explain multifactorial CYP2C19 inhibition.

Zhang H, Ragueneau-Majlessi I, Levy RH.

Drug Metab Lett. 2009 Dec;3(4):287-9.

PMID:
19995331
19.

Quantitative evaluation of pharmacokinetic inhibition of CYP3A substrates by ketoconazole: a simulation study.

Zhao P, Ragueneau-Majlessi I, Zhang L, Strong JM, Reynolds KS, Levy RH, Thummel KE, Huang SM.

J Clin Pharmacol. 2009 Mar;49(3):351-9. doi: 10.1177/0091270008331196.

PMID:
19246732
20.

Pharmacokinetics, safety, and tolerability of the new antiepileptic carisbamate in the elderly.

Levy R, Ragueneau-Majlessi I, Solanki B, Zannikos P, Yao C, Novak G.

Epilepsy Res. 2008 Mar;79(1):22-30. doi: 10.1016/j.eplepsyres.2007.12.013. Epub 2008 Feb 14.

PMID:
18280116

Supplemental Content

Loading ...
Support Center